Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Uppsala, November 15, 2022. Dicot's latest study of the mechanism of action of LIB-01, i.e., how the drug affects the body to achieve the desired effect, shows that it differentiates from today's potency drugs. This means that LIB-01 can be assumed to represent a new generation of potency drugs.
Dicot is developing a modern potency drug to treat erectile dysfunction and premature ejaculation better than existing medicines. As part of the long-term development work, studies are underway to map LIB-01's mechanism of action - that is, how the drug affects underlying processes in the body so that the desired effect occurs.
Results from a recent ex vivo study show that the mechanism of action of LIB-01 differentiates from today's potency drugs such as e.g., Viagra. These are significant results as today's potency drugs, with their mechanism of action, do not work optimally for all patients whereof approximately 35% do not have sufficient effect and many report unwanted side effects.
"The fact that we now can postulate that the mechanism of LIB-01 differentiates from current ED drugs is of great importance, and an indication that LIB-01 may represent a new generation of ED drugs", comments Professor Francois Giuliano, urologist specialized in sexual medicine and founder of Pelvipharm.
"With a different mechanism of action than today's drugs, we have a great potential to show that LIB-01 can treat sexual dysfunctions better than current treatments," says Elin Trampe, CEO at Dicot.